News
We are delighted to welcome Chloe Christie to The Williams Blood Cancer Research Group, where she will begin her PhD in October 2026. Chloe, a fourth-year Biological Sciences student at Glasgow Caledonian University, has become the first GCU student to receive a prestigious British Pharmacological Society PhD studentship. Funded through the inaugural Sir David Jack Scholarship programme, her project will investigate PROTACs, a promising new class of protein-degrading drugs, as a potential treatment for multiple myeloma.
Supervised by Dr Mark Williams and Dr Yvonne Dempsie, Chloe’s research will explore innovative ways to overcome treatment resistance and improve outcomes for blood cancer patients.
April 2026
A long term and key supporter of the WBCRG, has awarded the group a further £30,000 in funding for their AML and Myeloma-focused research studies. This is in addition to £70,000 previously awarded to the group by the charity. The Williams Blood Cancer Research Group is so very thankful and grateful for the continued support of their research by The Sylvia Aitken Charitable Trust.
December 2025
Dr Mark Williams was invited to present his group's research at the Festival of Genomics and Biodata in the ExCel Conference Centre in London
Investigating the Therapeutic Potential of PROTACS in Multiple Myeloma
January 29, 2025
Mr Stefan Corradini’s abstract has been accepted as a poster presentation at the British Society for Haematology's 65th Annual Scientific Meeting, 2025.
CBPD-409: A Novel CBP/p300 Degrader with Therapeutic Potential in Multiple Myeloma.
Impressively, Stefan has received a 2025 ASM Abstract Scholarship, with these scholarships supporting the best of haematology science and research by offering funding to presenters of high-scoring abstracts to facilitate attendance at the conference.
February, 2025.
A long term supporter of the WBCRG, has awarded the group a further £30,000 in funding for their AML and Myeloma-focused research studies. This is in addition to £40,000 previously awarded to the group by the charity. The Williams Blood Cancer Research Group is very thankful and grateful for the continued support of their research by The Sylvia Aitken Charitable Trust.
December 2024
Group's abstract accepted as a poster for presentation at the American Society of Hematology
2761 M2-like Macrophages Transfer Mitochondria to Acute Myeloid Leukaemia Cells Via Tunnelling Nanotubes Promoting Therapy Resistance.
Link to ABSTRACT
December 2024 | San Diego
Publication of the group's abstract in Blood
Investigating the therapeutic potential of Novel CBP/p300 Protein Degrader CBPD409 in Multiple Myeloma.
Link to ABSTRACT
November 5, 2024
.png)
Group contributed to a study, which was led by Dr. Kareem Azab's lab.
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.
The paper was published in Leukemia on August 30, 2024.
Link to PAPER
August 2024
Dr. Mark Williams was invited to give a talk on "Identifying and therapeutically targeting novel vulnerabilities in AML and Multiple Myeloma" at the Patrick G. Johston Centre for Cancer Research, Queen's University, Belfast.
June 2024
Mr. Ebubechukwu Nwuranma started his PhD studentship with the project title "Development of a novel platform lipid nanoparticle system to induce tailored immune responses for therapeutic benefits.
June 2024